Donation opens doors for Alzheimer’s study subjects
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$0 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*No charge for 4 weeks then price increases to the regular rate of $19.00 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.75/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 04/01/2019 (2527 days ago), so information in it may no longer be current.
A Winnipeg researcher who is studying a potential treatment for Alzheimer’s disease is looking for more participants for her program —and just got the funding to help more people access it.
Zahra Moussavi, a biomedical engineer and University of Manitoba professor, is analyzing the use of repetitive transcranial magnetic stimulation (rTMS) on subjects with early- to moderate-stage dementia and Alzheimer’s, which affects an estimated 22,500 Manitobans. Dementia has no known cure and is nearing pandemic levels worldwide, as the baby boom generation ages.
For roughly 30 minutes a day, five days a week, for four weeks, a magnetic coil is held over the patient’s head, sending 20 high-frequency pulses per second to the brain.
“When we give them at a high frequency, it excites the neurons,” Moussavi said. “It’s helping neurons that have become inactive.
“We don’t expect the treatment to make a miracle, but we have seen people who are responsive to rTMS,” said the researcher seeking to learn if the process — which has been used for decades to treat a number of neurological and psychiatric conditions — can reduce the effects of Alzheimer’s and fight the progression of the disease.
To do that, she needs at least 100 study participants. However, for people with dementia, getting around isn’t easy.
“Someone has to bring the patient every day,” said Moussavi, who received $1.8 million from the Weston Brain Institute in 2016 for the study, which she runs at three sites: in Winnipeg at Riverview Health Centre, Montreal and Melbourne, Australia.
Globally, it’s the largest study for the potential treatment of Alzheimer’s using the pulsating magnetic coil.
“Some patients have no one to drive them,” said Moussavi, who recently received a four-year, $400,000 donation to help with transportation costs of study participants in Manitoba.
“This donation allows people to come,” she said. So far, there have been participants from Winnipeg, Gimli, and as far away as a three-hour drive. “Some had family members here who they stayed with.”
With the recent donation, Moussavi can pay for participants to take a cab to and from Riverview, and open up the program to out-of-towners. “I can help them with $2,000 for the family to rent accommodations in Winnipeg for the duration of the treatment.”
So far, Moussavi, who is also studying the effect of brain exercises on dementia patients, has had 36 participants in the rTMS study.“Not everybody is responsive to rTMS,” she said.
The Alzheimer Society of Manitoba said it is interested in the program’s results. By using a control group and a treatment group, Moussavi’s study should highlight its effectiveness, said Norma Kirkby, the society’s program co-ordinator.
“It will be able to give good evidence on its outcomes,” Kirkby said. Those who are in the control group and not receiving rTMS are eligible to undergo treatments after completing the series.
The society has had feedback from some study subjects, saying the treatment was beneficial, and from others who said it made no difference, Kirkby said.
In the end, the hope is “everyone will know what its potential is.”
carol.sanders@freepress.mb.ca
Carol Sanders
Legislature reporter
Carol Sanders is a reporter at the Free Press legislature bureau. The former general assignment reporter and copy editor joined the paper in 1997. Read more about Carol.
Every piece of reporting Carol produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press‘s tradition, since 1872, of producing reliable independent journalism. Read more about Free Press’s history and mandate, and learn how our newsroom operates.
Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber.
Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
History
Updated on Saturday, January 5, 2019 8:45 AM CST: Final